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Inheritance of the T allele in exon 7 (position 18067) of the DNA repair gene XRCC3 has been reported to be
associated with susceptibility to melanoma in a study from Oxford. We report a study in which an attempt was made
to conﬁrm this association in a similar population. The most potent risk factor for melanoma in the general
population is a phenotype characterized by the presence of multiple melanocytic nevi: the atypical mole syndrome.
Our hypothesis is that the atypical mole syndrome may be a marker of genetic susceptibility to melanoma. We have
therefore investigated whether the XRCC3 polymorphism inﬂuences the nevus phenotype. The XRCC3 genotype
was investigated using PCR in a general-practice-based sample of 565 women and 475 patients from a cohort
enriched for the atypical mole syndrome, of whom 140 had had melanoma. Allele frequencies were the same in the
healthy women, the melanoma cases from this study, and the melanoma cases reported in the Oxford study, but
were different from those in the Oxford control group. We found no evidence therefore that the T allele of this
XRCC3 polymorphism is indicative of susceptibility to melanoma. There was a marginal relationship with nevus
phenotype, but this was no longer statistically signiﬁcant in multivariate analysis. The previous association
between XRCC3 and melanoma may be a result of the choice of control group and we emphasize the need for
appropriate choice of controls.
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Inheritance of the T allele in exon 7 (position 18067) of the
DNA X-ray repair cross-complementing gene 3 (XRCC3)
has been reported to be associated with susceptibility to
melanoma in a population from Oxford, UK (p¼ 0.004; odds
ratio 2.36) (Winsey et al, 2000) although this was not
confirmed in a US population (Duan et al, 2002). The
functional significance of the polymorphism is not yet
known. The most potent phenotypic risk factor for
melanoma in the general population is the atypical mole
syndrome (AMS) phenotype (Augustsson et al, 1990;
Halpern et al, 1991; Bataille et al, 1996). Our hypothesis is
that the AMS may be a marker of genetic susceptibility to
melanoma: that nevus genes may be low penetrance
melanoma susceptibility genes. We have therefore deter-
mined if the XRCC3 polymorphism influences the nevus
phenotype in two populations.
Results
Genotype frequencies (Table I) showed no significant
difference in distribution between the healthy women and
the AN/FM group (w2¼0.98 with two degrees of freedom,
p¼0.61). The T allele frequency was similar in the healthy
women, the AN/FM group who had melanoma, and in those
who did not. All groups were in Hardy–Weinberg equili-
brium.
In the AN/FM group the univariate analysis showed a
consistent increase in total number of nevi (p value for linear
trend 0.02) and number of atypical nevi (p value for linear
trend 0.05) with increasing numbers of T alleles (Table II). In
multivariate analyses, however, there was no evidence of a
relationship with genotype (Tables II, III) and the above trends
were not significant (p¼0.28 and p¼ 0.17, respectively).
No associations were seen between either total or atypical
nevus count and XRCC3 genotype, in univariate or multi-
variate analysis, amongst the GP group (Tables II, III).
Discussion
Allele frequencies were the same in the GP group, the
melanoma cases from this study, and the melanoma cases
reported in the Oxford study published earlier, but were
different from those in the Oxford control group (p¼0.001)
(Winsey et al, 2000). Therefore the disparity between our
findings and those of the Oxford group arises as a result of a
different prevalence of XRCC3 T alleles in the donors of
Abbreviations: AMS, atypical mole syndrome; AN/FM, study group
recruited in abnormal nevus phenotype and familial melanoma
research programme; XRCC3, X-ray repair cross-complementing
gene 3.
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Table I. Genotype frequencies in this study and in the studies reported by Duan et al (2002) and Winsey et al (2000)
This study UK,
AN/FM (n¼475)
This study UK controls
(GP group) (n¼565) Duan et al (2002), USA
Winsey et al
(2000), Oxford
Patients
without
melanoma
(n¼335)
Melanoma
cases
(n¼140)
Yorkshire
(n¼ 362)
Hertfordshire
(n¼203)
Cases
(n¼305)
Controls
(n¼319)
Oxford
melanoma
cases
(n¼125)
Donor
controls
in the
Oxford
study
(n¼211)
Mean age (sd) 40 (17.5) 48 (13.6) 36 (6.7) 37 (6.2) 49 51 52a
Female percentage 55 61 100 100 48 49 42
CC 135 50 140 69 119 116 39 110
n (%) (40%) (36%) (39%) (34%) (39%) (36%) (31%) (52%)
CT 160 68 170 101 148 158 65 78
n (%) (48%) (48%) (47%) (50%) (48%) (50%) (52%) (37%)
TT 40 22 52 33 38 45 21 23
n (%) (12%) (16%) (14%) (16%) (13%) (14%) (17%) (11%)
Frequency of T allele 36% 40% 38% 41% 37% 39% 43% 29%
Hardy–Weinbergb p¼ 0.48 p¼ 0.89 p¼ 0.97 p¼ 0.70 p¼ 0.44 p¼0.45 p¼0.49 p¼0.11
The GP group were female and the AN/FM group were of both sexes.
aMedian age.
bp value for test of departure from Hardy–Weinberg equilibrium.
Table II. Predictors of nevus phenotype: univariate analyses of nevus characteristics with genotype in both the AN/FM and the GP
groups
CC, mean (SD) CT, mean (SD) TT, mean (SD) ANOVA, p value Test for trend, p value
AN/FM group
AMS 0–5 (n¼ 475) (n¼ 185) (n¼ 228) (n¼62)
Log total nevus count 4.06 (1.20) 4.21 (1.20) 4.47 (1.19) 0.07 0.02
Log atypical nevus count 0.77 (0.99) 0.89 (1.02) 1.07 (1.08) 0.14 0.05
AMS score 1.89 (1.35) 2.11 (1.41) 2.31 (1.35) 0.09a 0.03a
AMS 2–5 (n¼ 289) (n¼ 103) (n¼ 143) (n¼43)
Log total nevus count 4.86 (0.70) 4.88 (0.66) 5.02 (0.62) 0.40 0.25
Log atypical nevus count 1.27 (1.05) 1.32 (1.02) 1.42 (1.06) 0.72 0.44
Probands AMS 0–5 (n¼ 174) (n¼ 58) (n¼90) (n¼26)
Log total nevus count 4.83 (0.92) 4.97 (0.86) 5.16 (0.60) 0.27 0.11
Log atypical nevus count 1.25 (1.06) 1.40 (1.05) 1.68 (0.96) 0.22 0.09
Probands AMS 2–5 (n¼ 157) (n¼ 51) (n¼82) (n¼24)
Log total nevus count 5.07 (0.66) 5.15 (0.54) 5.26 (0.49) 0.39 0.17
Log atypical nevus count 1.35 (1.06) 1.52 (1.01) 1.79 (0.90) 0.22 0.09
GP group
AMS 0–5 (n¼ 565) (n¼ 209) (n¼ 271) (n¼85)
Log total nevus count 3.74 (0.96) 3.69 (0.86) 3.62 (0.86) 0.61 0.33
Log atypical nevus count 0.17 (0.42) 0.14 (0.36) 0.14 (0.39) 0.77 0.55
AMS 2–5 (n¼ 107) (n¼ 50) (n¼43) (n¼14)
Log total nevus count 4.66 (0.60) 4.51 (0.61) 4.66 (0.66) 0.48 0.61
Log atypical nevus count 0.44 (0.65) 0.39 (0.60) 0.38 (0.68) 0.92 0.70
Nevus counts were log-transformed to reduce positive skew of the distributions.
aOrdinal regression.
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organs used as controls. The cause of death in UK
cadaveric donors, however, is nonrandom as the majority
die from intracranial hemorrhage (NHS UK Transplant). It is
not inconceivable that a DNA repair gene might play a role
in susceptibility to early stroke (Kim et al, 2001; Goto et al,
2002). Spurious correlations between genotypes and dis-
ease may arise by chance, or as a result of population
stratification (where disease and genotype are correlated in
the population, due to confounding, generally by ethnic or
regional differences in both allele frequencies and disease
rates (Thomas and Witte, 2002; Wacholder et al, 2002)).
There is also agreement that the practice of using
convenience samples as controls may give rise to false
positive associations, although the practice remains wide-
spread. Comparisons between our sampled groups are
subject to the criticisms outlined above, but the same
potential for bias does not exist within the two studies as
our controls were not selected by disease. The fact that the
subjects without melanoma are selected on the basis of
nevus phenotype would tend to minimize any differences in
allele frequencies for a true melanoma/nevus gene. None-
theless we believe that the results provide strong evidence
that the original association was spurious. Within the UK,
two studies have shown similar allele frequencies in two
sets of melanoma cases but different frequencies in the
controls. Furthermore the allele frequencies in our two UK
control groups (Yorkshire and Hertfordshire) and in the US
controls (Duan et al, 2002) were similar. It therefore seems
most likely that the Oxford controls, rather than the healthy
women studied here, are unrepresentative of the normal
population. The issue of control selection remains a critical
but contentious one.
Our study found no evidence that the T allele of this
XRCC3 polymorphism is indicative of susceptibility to an
atypical nevus phenotype. We did find a marginal relation-
ship between inheritance of the T allele and AMS score, the
number of nevi, and the number of atypical nevi (Table II) but
no significant association once appropriate corrections for
age, sex, and familial clustering were made (Table III). It is
not possible to exclude the possibility that there is a real
relationship between nevi and XRCC3, which would require
a larger study to explore.
Methods
565 white women were recruited from the general population via
general practices in Yorkshire and Hertfordshire (GP group). 475 white
subjects, of whom 140 had had melanoma, consisting of 174 probands
and their adult relatives, were studied from a cohort enriched for the
AMS as described previously (Bertram et al, 2002) (atypical nevi/familial
melanoma (AN/FM) group). Ethical approval was obtained from local
ethics committees prior to data collection.
Banal and atypical nevi were counted as previously described, and
the AMS score was computed (Bertram et al, 2002). DNA was
extracted from blood, and the XRCC3 polymorphism was detected
using PCR as described previously (Winsey et al, 2000).
Statistical analysis was performed using the statistical package
Stata (StataCorp, College Station, TX).
Primary analyses were based on the three XRCC3 genotypes (CC,
CT, TT) and secondary analyses examined trend. Associations between
nevus counts and XRCC3 genotype were analyzed using analysis of
variance and tests for linear trend. In the AN/FM group, ordinal
regression was used to estimate associations between XRCC3
genotype and AMS score. Analyses were repeated amongst probands
only and in subjects with an abnormal phenotype (AMS score 2–5).
Multivariate regression was also used, adjusting for age, sex (AN/
FM only), melanoma status (AN/FM only), and examiner. The AN/FM
analyses also took account of familial clustering by using random
effects models.
Table III. Predictors of nevus phenotype: multivariate analyses
of nevus characteristics with genotype in both the AN/FM and
the GP groups
Parameters in the model
Coefﬁcient
(standard error) p-value
Log total nevus count (AN/FM group)
Age 0.07 (0.01) o0.0001
Age-squared 0.001 (0.0002) o0.0001
Sex — females versus males 0.07 (0.09) 0.44
Melanoma — present versus
absent
0.61 (0.10) o0.0001
XRCC3 — CT versus CC 0.09 (0.10) 0.35
XRCC3 — TT versus CC 0.16 (0.14) 0.27
Log atypical nevus count (AN/FM group)
Age 0.03 (0.01) 0.05
Age-squared 0.0004 (0.0001) 0.005
Sex — females versus males 0.17 (0.08) 0.04
Melanoma — present versus
absent
0.59 (0.10) o0.0001
XRCC3 — CT versus CC 0.12 (0.09) 0.21
XRCC3 — TT versus CC 0.14 (0.14) 0.30
AMS score (AN/FM group)a
Age 0.10 (0.03) o0.0001
Age-squared 0.001 (0.0003) o0.0001
Sex — females versus males 0.15 (0.17) 0.37
Melanoma — present versus
absent
1.13 (0.18) o0.0001
XRCC3 — CT versus CC 0.35 (0.19) 0.06
XRCC3 — TT versus CC 0.29 (0.26) 0.26
Log total nevus count (GP group)b
XRCC3 — CT versus CC 0.06 (0.08) 0.49
XRCC3 — TT versus CC 0.12 (0.12) 0.31
Log atypical nevus count (GP group)b
XRCC3 — CT versus CC 0.03 (0.03) 0.35
XRCC3 — TT versus CC 0.04 (0.05) 0.46
Nevus counts were log-transformed to reduce positive skew of the
distributions. All analyses adjusted for examiner, and analyses of the AN/
FM group included family as a random effect.
aOrdinal regression.
bIn the GP group, analyses were adjusted for age and age squared as
in the AN/FM group, although the relationships were in this case not
significant.
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